TY - JOUR
T1 - Peptide-receptive class I major histocompatibility complex molecules on TAP-deficient and wild-type cells and their roles in the processing of exogenous antigens
AU - Song, R.
AU - Porgador, A.
AU - Harding, C. V.
PY - 1999/6/23
Y1 - 1999/6/23
N2 - These studies addressed the nature and origin of peptide-receptive class I major histocompatibility complex (MHC-I) molecules used to present exogenous antigens. Peptide-receptive Kb molecules in transporter for antigen presentation (TAP)1(-/-) and TAP1(+/+) macrophages were quantitated by exposing cells to exogenous ovalbumin (OVA)(257-264) peptide and then measuring OVA(257-264):Kb complexes with a T hybridoma assay or flow cytometry (using a complex-specific antibody). Relative to TAP1(+/+) cells, TAP1(-/-) cells had decreased levels of pre-existing cell-surface peptide- receptive MHC-I molecules at 37°. With continued exposure of viable cells to peptide, however, TAP1(-/-) and TAP1(+/+) cells formed similar levels of OVA(257-264):Kb complexes, suggesting that nascent labile MHC-I molecules were captured and stabilized by exogenous peptide. Brefeldin A inhibited generation of OVA(257-264):Kb complexes on TAP1(-/-) (but not TAP1(+/+)) cells at 37°, confirming the importance of a flux of unstable nascent MHC-I molecules in TAP1(-/-) cells at 37°. In contrast, at 26°both TAP1(-/-) and TAP1(+/+) cells expressed brefeldin A-resistant, peptide-receptive MHC-I molecules at similar levels. Alternate MHC-I processing of exogenous particulate antigen correlated with ability to present exogenous peptide. Thus, processing was brefeldin A-sensitive with TAP1(-/-) macrophages at 37°, but brefeldin A-resistant with TAP1(+/+) cells at 37°, as well as with TAP1(+/+) or TAP1(-/-) cells at 26°. We conclude that alternate MHC-I antigen processing normally utilizes pre-existing MHC-I molecules, but TAP1(- /-) cells at 37°mainly use nascent MHC-I molecules, because of a lack of pre-existing, stable, peptide-receptive MHC-I molecules. The results support a vacuolar processing mechanism with binding of peptides to MHC-I molecules in post-Golgi compartments or on the cell surface.
AB - These studies addressed the nature and origin of peptide-receptive class I major histocompatibility complex (MHC-I) molecules used to present exogenous antigens. Peptide-receptive Kb molecules in transporter for antigen presentation (TAP)1(-/-) and TAP1(+/+) macrophages were quantitated by exposing cells to exogenous ovalbumin (OVA)(257-264) peptide and then measuring OVA(257-264):Kb complexes with a T hybridoma assay or flow cytometry (using a complex-specific antibody). Relative to TAP1(+/+) cells, TAP1(-/-) cells had decreased levels of pre-existing cell-surface peptide- receptive MHC-I molecules at 37°. With continued exposure of viable cells to peptide, however, TAP1(-/-) and TAP1(+/+) cells formed similar levels of OVA(257-264):Kb complexes, suggesting that nascent labile MHC-I molecules were captured and stabilized by exogenous peptide. Brefeldin A inhibited generation of OVA(257-264):Kb complexes on TAP1(-/-) (but not TAP1(+/+)) cells at 37°, confirming the importance of a flux of unstable nascent MHC-I molecules in TAP1(-/-) cells at 37°. In contrast, at 26°both TAP1(-/-) and TAP1(+/+) cells expressed brefeldin A-resistant, peptide-receptive MHC-I molecules at similar levels. Alternate MHC-I processing of exogenous particulate antigen correlated with ability to present exogenous peptide. Thus, processing was brefeldin A-sensitive with TAP1(-/-) macrophages at 37°, but brefeldin A-resistant with TAP1(+/+) cells at 37°, as well as with TAP1(+/+) or TAP1(-/-) cells at 26°. We conclude that alternate MHC-I antigen processing normally utilizes pre-existing MHC-I molecules, but TAP1(- /-) cells at 37°mainly use nascent MHC-I molecules, because of a lack of pre-existing, stable, peptide-receptive MHC-I molecules. The results support a vacuolar processing mechanism with binding of peptides to MHC-I molecules in post-Golgi compartments or on the cell surface.
UR - http://www.scopus.com/inward/record.url?scp=0033049945&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2567.1999.00759.x
DO - 10.1046/j.1365-2567.1999.00759.x
M3 - Article
C2 - 10447748
AN - SCOPUS:0033049945
SN - 0019-2805
VL - 97
SP - 316
EP - 324
JO - Immunology
JF - Immunology
IS - 2
ER -